logo
Share SHARE
FONT-SIZE Plus   Neg

Merck KGaA Q2 Loss Reduces; Boosts Annual Outlook - Quick Facts

German drugs and chemicals firm Merck KGaA (MKGAY.PK) reported a narrower second-quarter 2012 loss after tax of 60.5 million euros, compared with 86.8 million euros last year. On a reported basis, quarterly loss per share was 0.29 euros, narrower than a 0.41 euros loss a year before, the company added. Adjusted for one-time costs, earnings per share pre totaled 1.92 euros, up 20% from the prior year's 1.60 euros.

Merck's second-quarter total revenues rose 12% to 2.85 billion euros, from 2.555 billion euros in the 2011 second quarter. Quarterly sales went up 11% to 2.74 billion euros, from 2.47 billion euros in the year-ago quarter, reflecting an organic sales growth of 5.1%, a 5.4% positive benefit from foreign exchange rates and a 0.5% rise from acquisitions and divestments.

Based on the second-quarter results, Merck has upgraded its full-year total revenues and EBITDA pre guidance for 2012. The company now sees annual EBITDA pre one-time items of 2.85 billion euros - 2.95 billion euros, and total revenues of around 10.7 billion euros. Previously, Merck Group estimated EBITDA pre one-time items of 2.8 billion euros - 2.9 billion euros, and total revenues of about 10.5 billion euros for 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The holiday throng seeking to take a flight out to their preferred destinations at the at New York's Kennedy International Airport ahead of the Memorial Day holiday were in for a rude shock. Technology played a spoilsport, as a computer system broke down Sunday evening at a terminal, causing flight delays and cancellations that resulted in manual check-in process for thousands of holiday passeng The month of May saw the FDA greenlight 5 new drugs, including 1 new molecular entity, and surprisingly turn down 1 drug candidate, whose approval was considered a no-brainer by some experts. Lab equipment maker Thermo Fisher Scientific Inc. has agreed to acquire electron microscope maker FEI Co. for about $4.2 billion in cash, the two companies said Friday. Thermo Fisher noted that FEI's electron microscopy platform will complement its own mass spectrometry systems to accelerate advancements in structural biology.
comments powered by Disqus
Follow RTT